Ambrx Biopharma Inc. Stock News

Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.

Fintel reports that Darwin Global Management has filed a 13D form with the SEC disclosing ownership of 79.13MM shares of Ambrx Biopharma Inc.

Ambrx is a clinical-stage biotech and is not profitable. The company's lead therapy is ARX788, which is being tested as an add-on therapy to treat breast cancer.

Analysts have recently rated Ambrx Biopharma, Inc (NYSE: AMAM) a Moderate Buy, even though its $8.50 price target represents a 33% downside. While its current $12.54 share price–and $390.06 million

Use these tips for staying disciplined when it comes to investing in penny stocks The post How to Stay Disciplined When Investing in Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and

Ambrx Biopharma (NYSE: AMAM ) stock is falling on Friday but it's not due to any news released by the company today. Instead, it looks like shares are retreating from a rally on Thursday.

Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.

Short squeeze stocks to watch. The post Penny Stocks To Buy?

Use these tips for evaluating penny stocks to buy The post How to Find and Evaluate Penny Stocks For Your Portfolio  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c

In a topsy-turvy session today, investors may be intrigued by some of the biggest gainers and decliners as most stocks hold around the flat line. Among the leaders in terms of percentage gains today i

Conference call to discuss outcome of the strategic review that was initiated in August 2022 Conference call to discuss outcome of the strategic review that was initiated in August 2022

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision B

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision B

Ambrx Biopharma Inc. (NYSE:AMAM ) Q4 2021 Earnings Conference Call April 26, 2022 4:30 PM ET Company Participants Feng Tian – Chief Executive Officer Sonja Nelson – Chief Financial Officer Laurenc

Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE: AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in t